Foster Dykema Cabot & Co. Inc. MA held its position in Eli Lilly and Company (NYSE:LLY) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 18,796 shares of the company’s stock at the close of the second quarter. Foster Dykema Cabot & Co. Inc. MA’s holdings in Eli Lilly and were worth $1,547,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other hedge funds and other institutional investors have also added to or reduced their stakes in LLY. BlackRock Inc. raised its holdings in Eli Lilly and by 2,628.5% in the 1st quarter. BlackRock Inc. now owns 62,260,488 shares of the company’s stock worth $5,236,731,000 after purchasing an additional 59,978,664 shares during the period. Vanguard Group Inc. raised its holdings in Eli Lilly and by 3.3% in the 1st quarter. Vanguard Group Inc. now owns 68,597,006 shares of the company’s stock worth $5,769,694,000 after purchasing an additional 2,181,701 shares during the period. Winslow Capital Management LLC raised its holdings in Eli Lilly and by 79.7% in the 1st quarter. Winslow Capital Management LLC now owns 3,875,968 shares of the company’s stock worth $326,008,000 after purchasing an additional 1,719,538 shares during the period. Harbour Capital Advisors LLC raised its holdings in Eli Lilly and by 7,919.1% in the 2nd quarter. Harbour Capital Advisors LLC now owns 1,705,338 shares of the company’s stock worth $20,721,000 after purchasing an additional 1,684,072 shares during the period. Finally, Renaissance Technologies LLC raised its holdings in Eli Lilly and by 93.6% in the 1st quarter. Renaissance Technologies LLC now owns 2,980,400 shares of the company’s stock worth $250,681,000 after purchasing an additional 1,441,200 shares during the period. 75.72% of the stock is owned by institutional investors.
Eli Lilly and Company (NYSE:LLY) opened at 87.08 on Friday. The company has a 50-day moving average price of $82.21 and a 200 day moving average price of $82.15. Eli Lilly and Company has a 12 month low of $64.18 and a 12 month high of $89.09. The stock has a market capitalization of $91.87 billion, a price-to-earnings ratio of 37.68 and a beta of 0.34.
Eli Lilly and (NYSE:LLY) last issued its quarterly earnings results on Tuesday, July 25th. The company reported $1.11 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.05 by $0.06. The company had revenue of $5.82 billion during the quarter, compared to the consensus estimate of $5.60 billion. Eli Lilly and had a return on equity of 28.71% and a net margin of 11.12%. Eli Lilly and’s revenue was up 7.8% on a year-over-year basis. During the same period in the previous year, the firm posted $0.86 EPS. Equities analysts predict that Eli Lilly and Company will post $4.16 earnings per share for the current year.
In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 220,000 shares of the business’s stock in a transaction on Monday, July 31st. The stock was sold at an average price of $83.09, for a total value of $18,279,800.00. Following the completion of the transaction, the insider now directly owns 124,049,283 shares in the company, valued at approximately $10,307,254,924.47. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders sold a total of 990,000 shares of company stock valued at $82,949,650 over the last quarter. 0.20% of the stock is currently owned by insiders.
ILLEGAL ACTIVITY NOTICE: “Eli Lilly and Company (LLY) Stake Held by Foster Dykema Cabot & Co. Inc. MA” was reported by Transcript Daily and is the sole property of of Transcript Daily. If you are accessing this story on another website, it was stolen and reposted in violation of U.S. & international copyright legislation. The legal version of this story can be viewed at https://transcriptdaily.com/2017/10/08/eli-lilly-and-company-lly-stake-held-by-foster-dykema-cabot-co-inc-ma.html.
A number of equities analysts recently weighed in on the company. Morgan Stanley set a $86.00 price target on Eli Lilly and and gave the stock a “hold” rating in a report on Friday. Goldman Sachs Group, Inc. (The) reissued a “buy” rating and set a $95.00 target price (up previously from $92.00) on shares of Eli Lilly and in a report on Thursday. Cowen and Company reissued a “buy” rating and set a $95.00 target price on shares of Eli Lilly and in a report on Wednesday. BMO Capital Markets reissued a “sell” rating and set a $71.00 target price on shares of Eli Lilly and in a report on Thursday, September 28th. Finally, Zacks Investment Research raised Eli Lilly and from a “hold” rating to a “buy” rating and set a $94.00 target price for the company in a report on Monday, July 17th. Three research analysts have rated the stock with a sell rating, seven have assigned a hold rating and twelve have issued a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $88.42.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.